ReviewGene therapy2005
Downstream processing of viral vectors and vaccines.
Review in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 171 citations in OpenAlex.
- Development and Validation of an Antigen-Capture ELISA for Quantitative Detection of Donkey-Origin Rotavirus: Application in Vaccine Manufacturing Process Monitoring.Microorganisms · 2026Article
- Progress in the research and development of oncolytic virus therapies.Frontiers in pharmacology · 2026Review
- Tunable retention and recovery via pore-to-particle interactions in amine functionalized micro- and ultrafiltration Membranes: Towards scalable viral vector purification.Journal of membrane science · 2026Article
- Integrated Analytical Techniques to Investigate the Effect of the Freezing/Thawing Cycles on the Non-replicating Recombinant Chimpanzee Adenovirus Viral Vector COVID-19 Vaccine.AAPS PharmSciTech · 2025Article
- Defining a Simplified Process in Yeast for Production of Enveloped VLP Dengue Vaccine.Bioengineering (Basel, Switzerland) · 2025Article
- Temperature-modulated separation of therapeutic cells, viral vectors, and exosomes using functional polymers.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Review
- Applications of virus-like particles in the prevention of protozoan parasite infection.Nanomedicine (London, England) · 2025Review
- Membrane Filtration of Nanoscale Biomaterials: Model System and Membrane Performance Evaluation for AAV2 Viral Vector Clarification and Recovery.Nanomaterials (Basel, Switzerland) · 2025Article
- Cowpea mosaic virus intratumoral immunotherapy maintains stability and efficacy after long-term storage.Bioengineering & translational medicine · 2024Article
- Authorizing of Immunogenicity of Concentrated and Purified Newcastle Disease Virus V4 Strain using Downstream Processing.Archives of Razi Institute · 2024Article
- Investigating dynamics of lentiviral vector secretion from HEK293T producer cells using a fractionated perfusion system.Biotechnology journal · 2024Article
- Dental Stem Cell-Derived Exosomes: A Review of Their Isolation, Classification, Functions, and Mechanisms.Stem cells international · 2024Review
- Poxvirus sensitivity of a novel diploid sheep embryonic heart cell line.Archives of virology · 2023Article
- Efficient clinical-grade γ-retroviral vector purification by high-speed centrifugation for CAR T cell manufacturing.Molecular therapy. Methods & clinical development · 2023Article
- Lessons learned from COVID-19 pandemic: Vaccine platform is a key player.Process biochemistry (Barking, London, England) · 2023Article
- Size-selective downstream processing of virus particles and non-enveloped virus-like particles.Frontiers in bioengineering and biotechnology · 2023Review
- Platforms, advances, and technical challenges in virus-like particles-based vaccines.Frontiers in immunology · 2023Review
- Article
- A Summary of Practical Considerations for the Application of the Steric Exclusion Chromatography for the Purification of the Orf Viral Vector.Membranes · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral vectors and viral vaccines more and more play an important role in current medical approaches. Gene vectors like adenoviruses, adeno-associated viruses or retroviruses are the vehicles being developed for delivering genetic material to the target cell in gene therapy. Viral vaccines, like attenuated or inactivated rabies virus, influenza virus or hepatitis virus vaccines, are powerful tools to limit the number of serious viral infections and pandemics. Higher safety demands, that is, reduction of side effects, by regulatory authorities like Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products (EMEA), nowadays force developers as well as manufacturers to improve their production and purification processes for viral vectors and vaccines. Like for influenza viral vaccines, manufacturers begin to switch from egg cultivation to mammalian cell culture systems. Also within the purification procedure, a clear trend from classical purification methods like sucrose gradient centrifugation towards more sophisticated techniques like tangential flow filtration and liquid chromatography can be observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.